Eli Lilly (LLY) is higher after Chinese regulators approve diabetes drug in China. Diane King Hall discusses this as Eli Lilly’s Phase 3 study of Crohn’s disease treatment achieves “meaningful improvements.” Eli Lilly hit a new all-time high today. Tune in to find out more about the stock market today.
Next Gen Investing
21 May 2024
SHARE